SCHEMBL7868697

SCHEMBL7868697

CC(C)(C)OC(=O)N(CCCCNC(=O)C(F)(F)F)Cc1cccc2nccn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.53
SSTR4 P31391 1/20 0.36
RORC P51449 1/20 0.33
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
BRD4 O60885 1/20 0.31
NAMPT P43490 2/20 0.31
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
EPHX1 P07099 1/20 0.31
CPB2 Q96IY4 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7870228 0.93 CA14 (0.44) CA14SSTR4RORCHDAC3HDAC1
SCHEMBL7863583 0.86 CA14 (0.36) CA14SSTR4RORCHDAC3HDAC1
SCHEMBL7875500 0.85 CA14 (0.35) CA14SSTR4RORCHDAC3HDAC1
SCHEMBL7863559 0.83 SSTR4 (0.37) CA14SSTR4RORCCPB2
SCHEMBL7875425 0.80 CA14 (0.49) CA14SSTR4
SCHEMBL7868728 0.77 CA3 (0.43) CA14ALDH1A1POLBSMN1; SMN2MEN1
SCHEMBL7872296 0.74 CA14 (0.41) CA14SSTR4
SCHEMBL1274571 0.72 CA14 (1.00) CA14SSTR4ALDH1A1POLBSMN1; SMN2
SCHEMBL7871566 0.71 CA14 (0.35) CA14SSTR4HDAC3HDAC1HDAC2
SCHEMBL7868751 0.71 CA14 (0.35) CA14SSTR4HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010051631-A1 Tricyclic compounds, their production and use TAKATANI MUNEO (JP) 2001-12-13 US disclosed
US-6251905-B1 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
US-5958942-A HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US disclosed
EP-0771319-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1997-05-07 EP disclosed
WO-1996002542-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051631-A1 Tricyclic compounds, their production and use PDGFA, HGF, REN CA14 4338/4885SSTR4 1397/4885RORC 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.